EA201792374A1 - Азабензимидазолы и их применение в качестве модуляторов рецептора ampa - Google Patents

Азабензимидазолы и их применение в качестве модуляторов рецептора ampa

Info

Publication number
EA201792374A1
EA201792374A1 EA201792374A EA201792374A EA201792374A1 EA 201792374 A1 EA201792374 A1 EA 201792374A1 EA 201792374 A EA201792374 A EA 201792374A EA 201792374 A EA201792374 A EA 201792374A EA 201792374 A1 EA201792374 A1 EA 201792374A1
Authority
EA
Eurasian Patent Office
Prior art keywords
azabenzimidazoles
application
receptor modulators
ampa receptor
formula
Prior art date
Application number
EA201792374A
Other languages
English (en)
Other versions
EA033281B1 (ru
Inventor
Синтия Г.Б. Берри
Ган Чэнь
Фабрис Лоик Журдан
Терри Патрик Леболд
Дэвид Вэй Линь
Мигель Анхель Пена Пиньон
Сучитра Равула
Брэдли М. Савалль
Девин М. Свенсон
Дунпэй У
Вэй Чжан
Майкл К. Эмерикс
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201792374A1 publication Critical patent/EA201792374A1/ru
Publication of EA033281B1 publication Critical patent/EA033281B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

В заявке предложены соединения формулы (I) и их фармацевтически приемлемые соли, N-оксиды или сольватыТакже предложены фармацевтические композиции, содержащие соединения формулы (I), и способы применения соединений формулы (I).
EA201792374A 2015-04-29 2016-04-28 Азабензимидазолы и их применение в качестве модуляторов рецептора ampa EA033281B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154313P 2015-04-29 2015-04-29
PCT/US2016/029801 WO2016176460A1 (en) 2015-04-29 2016-04-28 Azabenzimidazoles and their use as ampa receptor modulators

Publications (2)

Publication Number Publication Date
EA201792374A1 true EA201792374A1 (ru) 2018-05-31
EA033281B1 EA033281B1 (ru) 2019-09-30

Family

ID=56008859

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792374A EA033281B1 (ru) 2015-04-29 2016-04-28 Азабензимидазолы и их применение в качестве модуляторов рецептора ampa

Country Status (39)

Country Link
US (4) US11312712B2 (ru)
EP (3) EP3901153A1 (ru)
JP (2) JP6800886B2 (ru)
KR (2) KR20170140382A (ru)
CN (1) CN107835814B (ru)
AR (1) AR104447A1 (ru)
AU (2) AU2016255434C1 (ru)
BR (2) BR122023023802A2 (ru)
CA (1) CA2983826A1 (ru)
CO (1) CO2017011017A2 (ru)
CR (1) CR20170484A (ru)
CY (1) CY1124059T1 (ru)
DK (1) DK3288940T5 (ru)
EA (1) EA033281B1 (ru)
EC (1) ECSP17074645A (ru)
ES (1) ES2865330T3 (ru)
GT (1) GT201700231A (ru)
HK (1) HK1252249A1 (ru)
HR (1) HRP20210403T1 (ru)
HU (1) HUE053943T2 (ru)
IL (1) IL254848B (ru)
JO (1) JO3654B1 (ru)
LT (1) LT3288940T (ru)
MA (1) MA41988B1 (ru)
MD (1) MD3288940T2 (ru)
MX (1) MX2017013886A (ru)
MY (1) MY194104A (ru)
NI (1) NI201700129A (ru)
PH (1) PH12017501816A1 (ru)
PL (1) PL3288940T3 (ru)
PT (1) PT3288940T (ru)
RS (1) RS61688B1 (ru)
SG (1) SG11201708190UA (ru)
SI (1) SI3288940T1 (ru)
TW (1) TWI706952B (ru)
UA (1) UA120304C2 (ru)
UY (1) UY36654A (ru)
WO (1) WO2016176460A1 (ru)
ZA (1) ZA201708065B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016255431B2 (en) * 2015-04-29 2020-05-07 Janssen Pharmaceutica Nv Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators
CN107383004B (zh) * 2017-07-05 2020-04-17 浙江大学 2-氨基咪唑并吡啶类衍生物及制备和应用
EP3679027A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydrobenzimidazolones
US11447488B2 (en) 2017-10-06 2022-09-20 Takeda Pharmaceutical Company Limited Heterocyclic compounds
KR20210125471A (ko) 2018-10-05 2021-10-18 안나푸르나 바이오, 인코포레이티드 Apj 수용체 활성과 관련된 병태를 치료하기 위한 화합물 및 조성물
CA3118218A1 (en) * 2018-10-30 2020-05-07 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
WO2021012049A1 (en) * 2019-07-22 2021-01-28 Repare Therapeutics Inc. Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors
US20240076285A1 (en) * 2020-12-16 2024-03-07 Shankar Venkatraman Compounds and compositions for treating conditions associated with sting activity
CN114591338B (zh) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途
CN115304599A (zh) * 2022-09-20 2022-11-08 浙大宁波理工学院 一种3-溴-6-异丙基-1氢-哌咯[2，3-b]并吡啶及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
CN1051313A (zh) 1990-11-07 1991-05-15 鞍山市振东工业尼龙厂 尼龙球磨罐及其热装工艺
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
TW251284B (ru) * 1992-11-02 1995-07-11 Pfizer
AU685881B2 (en) * 1994-02-10 1998-01-29 Pfizer Inc. 5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
UA54403C2 (ru) 1996-10-01 2003-03-17 Н'Юросерч А/С Производные индол-2,3-дион-3-оксима, фармацевтическая композиция, способ лечения расстройства или заболевания млекопитающих, в том числе человека и способ получения производных индол-2,3-дион-3-оксима
DE19812331A1 (de) 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
JP2002519373A (ja) 1998-07-02 2002-07-02 エーザイ株式会社 製薬組成物及びそれらの使用
EP1139754A4 (en) 1998-12-31 2002-12-18 Sugen Inc 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATION OF PROTEIN KINASE ACTIVITY AND IN CANCER CHEMOTHERAPY
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
AU2001282865A1 (en) 2000-08-11 2002-02-25 Eli Lilly And Company Heterocyclic sulfonamide derivatives
US6548576B1 (en) 2001-11-07 2003-04-15 Bourns, Inc. Epoxy formulation adapted to be used in conjunction with no-lead solder in electronic components
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
CA2576765C (en) * 2004-09-03 2013-05-28 Applied Research Systems Ars Holding N.V. Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors
KR20130091791A (ko) 2005-09-30 2013-08-19 글락소 그룹 리미티드 Ｍ１ 수용체에서 활성을 갖는 화합물 및 그의 의약적 용도
WO2007135529A2 (en) 2006-05-23 2007-11-29 Pfizer Products Inc. Azabenzimidazolyl compounds as mglur2 potentiators
EP2086643B1 (en) 2006-11-03 2011-03-23 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
WO2008113795A1 (en) 2007-03-20 2008-09-25 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
GB0711089D0 (en) 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009067607A2 (en) 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
US8450343B2 (en) * 2007-12-06 2013-05-28 Xianhai Huang Gamma secretase modulators
TW201012803A (en) * 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
WO2010005528A2 (en) * 2008-06-30 2010-01-14 Ironwood Pharmaceuticals Incorporated Pyrrolopyridine carboxylic acid derivatives
GB0822425D0 (en) 2008-12-09 2009-01-14 Glaxo Group Ltd Compounds
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
WO2011156245A2 (en) * 2010-06-09 2011-12-15 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
WO2012020848A1 (en) 2010-08-10 2012-02-16 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2012021382A1 (en) 2010-08-12 2012-02-16 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
US9481677B2 (en) 2011-10-31 2016-11-01 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
WO2013130501A1 (en) * 2012-03-01 2013-09-06 The Board Of Regents Of The University Of Texas System Bivalent ampa receptor positive allosteric modulators
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
JO3225B1 (ar) 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
PE20151332A1 (es) 2013-02-19 2015-09-20 Pfizer Compuestos de azabencimidazol

Also Published As

Publication number Publication date
JP2018518462A (ja) 2018-07-12
DK3288940T5 (da) 2021-09-20
HRP20210403T1 (hr) 2021-10-29
JO3654B1 (ar) 2020-08-27
BR112017023147A2 (pt) 2018-07-10
JP2021042230A (ja) 2021-03-18
UY36654A (es) 2016-10-31
EA033281B1 (ru) 2019-09-30
PL3288940T3 (pl) 2021-07-12
JP6800886B2 (ja) 2020-12-16
EP3288940B9 (en) 2021-07-21
MY194104A (en) 2022-11-11
PH12017501816A1 (en) 2018-04-23
AU2020210231B2 (en) 2021-07-22
ZA201708065B (en) 2019-09-25
CO2017011017A2 (es) 2018-03-20
US20210284641A1 (en) 2021-09-16
US20230110576A1 (en) 2023-04-13
SG11201708190UA (en) 2017-11-29
GT201700231A (es) 2018-12-20
AU2016255434A1 (en) 2017-10-26
EP3288940B1 (en) 2021-02-24
UA120304C2 (uk) 2019-11-11
AR104447A1 (es) 2017-07-19
BR122023023802A2 (pt) 2023-12-26
MX2017013886A (es) 2018-03-12
EP3288940A1 (en) 2018-03-07
AU2016255434B2 (en) 2020-05-14
CA2983826A1 (en) 2016-11-03
TWI706952B (zh) 2020-10-11
MA41988A (fr) 2018-07-03
NZ736057A (en) 2023-08-25
MD3288940T2 (ro) 2021-08-31
NI201700129A (es) 2019-05-10
CY1124059T1 (el) 2022-05-27
PT3288940T (pt) 2021-04-30
EP3901153A1 (en) 2021-10-27
MA41988B1 (fr) 2021-03-31
JP7026194B2 (ja) 2022-02-25
HUE053943T2 (hu) 2021-08-30
HK1252249A1 (zh) 2019-05-24
KR20240017991A (ko) 2024-02-08
WO2016176460A1 (en) 2016-11-03
US11312712B2 (en) 2022-04-26
EP4144736A1 (en) 2023-03-08
RS61688B1 (sr) 2021-05-31
CR20170484A (es) 2018-02-26
DK3288940T3 (da) 2021-05-25
ECSP17074645A (es) 2018-02-28
SI3288940T1 (sl) 2021-07-30
CN107835814B (zh) 2021-07-23
AU2020210231A1 (en) 2020-08-20
KR20170140382A (ko) 2017-12-20
TW201708217A (zh) 2017-03-01
IL254848A0 (en) 2017-12-31
LT3288940T (lt) 2021-05-10
AU2016255434C1 (en) 2021-09-23
IL254848B (en) 2021-01-31
US20180118740A1 (en) 2018-05-03
BR112017023147B1 (pt) 2024-04-30
CN107835814A (zh) 2018-03-23
US20230114165A1 (en) 2023-04-13
ES2865330T3 (es) 2021-10-15

Similar Documents

Publication Publication Date Title
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
EA201691302A1 (ru) Новые гетероциклические соединения
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
MX2017008520A (es) Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).
MX2017013877A (es) Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201991700A1 (ru) Селективные ингибиторы jak1
PH12019501079A1 (en) Magl inhibitors
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
EA201691674A1 (ru) 1,2-замещенные циклопентаны в качестве антагонистов рецептора орексина
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
ZA201903291B (en) Fused bicylic pyridine compounds and their use as ampa receptor modulators
TR201901977T4 (tr) Cxcr3 reseptörü modülatörleri olarak (r)-2-metil-piperazin türevleri.
TR201904639T4 (tr) Muskarinik M1 reseptörü pozitif allosterik modülatörler.
EA201692227A1 (ru) Производные сложных аминоэфиров
EA201991045A1 (ru) Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора
MX2017013885A (es) Compuestos de indolona y su uso como moduladores del receptor ampa.
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7
MX2016015959A (es) Derivados de carbamato los cuales son tanto inhibidores de la enzima fosfodiesterasa 4 (pde4) como antagonistas del receptor muscarinico m3.
EA201600166A1 (ru) Производные пиперидина и азепина как модуляторы рецептора прокинетицина